WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world’s leading pharmaceutical and biotechnology companies, today announced $5.0 million of new business contracts with several multinational as well as smaller biopharmaceutical companies. The therapeutic areas included in these awards are cardiovascular diseases, oncology, diabetes, and infectious diseases. Services, which will be provided in both North America and Europe, include medical/scientific consulting, data management, regulatory affairs, project management, field monitoring, and medical monitoring/writing. Revenue recognition for many of these contracts will begin in the current third quarter of 2008 with the remainder expected to occur on a proportional performance basis as services are performed on each project.
